Compare EVG & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Current Price
| Metric | EVG | NTHI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.9M | 114.6M |
| IPO Year | 2004 | N/A |
| Metric | EVG | NTHI |
|---|---|---|
| Price | $10.75 | $4.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 29.6K | ★ 94.9K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.40 | $3.71 |
| 52 Week High | $11.45 | $12.99 |
| Indicator | EVG | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 45.30 |
| Support Level | $10.62 | $4.49 |
| Resistance Level | $10.94 | $5.78 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 52.17 | 26.46 |
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.